James Mcswiggen

USPTO Granted Patents = 16 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 14 (Patent Applications = 23)

Average Co-Inventor Count = 2.1

ph-index = 5

Forward Citations = 197(Granted Patents)

Company Filing History:

11 out of 2,405

Merck Sharp + Dohme Corp.

patents

4 out of 138

Sirna Therapeutics, Inc.

Years Active: 2010-2015

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9074205 - Nicked or gapped nucleic acid molecules and uses thereof (2015-07-07),

2. 8618277 - RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) (2013-12-31),

3. 8268986 - RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) (2012-09-18),

4. 8242257 - RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) (2012-08-14),

5. 8236944 - RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) (2012-08-07),

6. 8153778 - RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) (2012-04-10),

7. 8017765 - RNA interference mediated treatment of alzheimer's disease using short interfering nucleic acid (siNA) (2011-09-13),

8. 8013146 - RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) (2011-09-06),

9. 7935812 - RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) (2011-05-03),

10. 7923549 - RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) (2011-04-12),

11. 7910725 - RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) (2011-03-22),

12. 7897756 - RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA) (2011-03-01),

13. 7897755 - RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) (2011-03-01),

14. 7893248 - RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) (2011-02-22),

15. 7858771 - RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA) (2010-12-28),

Title: Innovations of James Mcswiggen

Introduction

James Mcswiggen is a prominent inventor based in Bothell, WA (US), known for his significant contributions to the field of molecular biology. With a total of 16 patents to his name, he has made remarkable advancements in gene expression modulation and therapeutic applications.

Latest Patents

One of Mcswiggen's latest patents is titled "Nicked or gapped nucleic acid molecules and uses thereof." This invention provides meroduplex ribonucleic acid molecules (mdRNA) that can decrease or silence target gene expression. The mdRNA comprises at least three strands that form non-overlapping double-stranded regions separated by a nick or gap, with one strand being complementary to a target gene RNA. Additionally, the patent outlines methods for decreasing expression of a target gene in a cell or subject to treat diseases related to altered gene expression.

Another notable patent is "RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)." This invention focuses on methods and reagents that modulate gene expression for various applications, including therapeutic and diagnostic uses. It involves synthetic chemically modified small nucleic acid molecules capable of mediating RNA interference against target nucleic acid sequences, which can be beneficial in treating diseases that respond to gene expression modulation.

Career Highlights

Throughout his career, Mcswiggen has worked with leading companies in the biotechnology sector, including Merck Sharp & Dohme Corporation and Sirna Therapeutics, Inc. His work has significantly impacted the development of innovative therapies and diagnostic tools.

Collaborations

Mcswiggen has collaborated with notable professionals in the field, including Leonid Beigelman and David Morrissey. These collaborations have further enhanced his research and contributions to molecular biology.

Conclusion

James Mcswiggen's innovative work in gene expression modulation and his numerous patents highlight his importance in the field of molecular biology. His contributions continue to pave the way for advancements in therapeutic applications and genetic research.

This text is generated by artificial intelligence and may not be accurate.